NUSANTICS | About Us

About Us

The Most Established Precision Molecular Diagnostics Company in Indonesia

Founded in 2020, Nusantics changed the molecular diagnostics landscape in Indonesia. Our technology has been used in more than 8 million tests during the COVID-19 pandemic. Now, we look to expand our technology to change the way we diagnose communicable diseases and oncology.

Leading the Way in Molecular Diagnostics

At Nusantics, we believe that molecular diagnosis should be accessible, affordable, and at a massive scale. Our products supports our customers across the continuum of molecular diagnostics. From the novel, non-invasive sampling method, DNA and RNA extraction, to PCR and NGS kits targeting single or multiple molecular target, and bioinformatics pipeline to analyze and interpret molecular data to deliver valuable insights.

Our Vision

We envision a healthy world enabled by genomics, microbiomics, and precision medicine

Our Mission

To close the diagnostics gap and improve healthcare outcome for both humans and animals

Our Core Values

The Principle to Guide Us on Our Journey

They embody what we stand for and guide our approach to how we build our product to improve healthcare outcomes.

Innovation

The foundation of imagination and creativity, embracing challenges, and openness to change.

Collaboration

Building an environment of trust, teamwork & collaboration, and valuing people internally and externally.

Integrity

Embedding every action with integrity, respect, and a commitment to ethical conduct, even in the absence of oversight.

Our Story

The Journey that Shapes Our Mission

Nusantics's journey began in 2020 with a research focus on how microbiome affects our health. Since the COVID-19 pandemic, Our focus shifted to democratize molecular diagnosis.

The founding of Nusantics (2020)
Nusantics was founded to personalize skin health with its novel Biome Scan. We are backed by East Ventures.
The launching of mBioCoV-19 (2020)
COVID-19 was declared a pandemic in Indonesia. We helped to make COVID-19 PCR testing more accessible with our BioCoV-19 and mBioCoV-19 in collaboration with Biofarma. Since then, we pivoted to building precision molecular diagnostics.
The launching of BioSaliva and VarScreen (2021)
Together with Biofarma, Nusantics released the non-invasive sampling method for COVID-19 PCR using gargle, named BioSaliva. VarScreen was launched to help diagnose the COVID-19 variant without Whole Genome Sequencing, reducing the cost of testing.
Illumina invested in Nusantics and the introduction of ShrimProtect and CeKolam